Advancements and challenges in CAR T cell therapy in autoimmune diseases.
Journal
Nature reviews. Rheumatology
ISSN: 1759-4804
Titre abrégé: Nat Rev Rheumatol
Pays: United States
ID NLM: 101500080
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
accepted:
28
06
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
6
8
2024
Statut:
aheadofprint
Résumé
Chimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for patients with relapsed or refractory B cell malignancies. In addition, the administration of genetically modified T cells with the capacity to deplete B cells and/or plasma cells has tremendous therapeutic potential in autoimmune diseases. In the past few years, CD19-based and B cell maturation antigen (BCMA)-based CAR T cell therapies have been applied to various B cell-mediated autoimmune diseases including systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, neuromyelitis optica spectrum disorder, myasthenia gravis and multiple sclerosis. The scientific rationale behind this approach is that deep depletion of B cells, including autoreactive B cell clones, could restore normal immune function, referred to as an immune reset. In this Review, we discuss important aspects of CAR T cell therapy in autoimmune disease, including considerations relating to patient selection, safety, efficacy and medical management. These considerations are based on the early experiences of CAR T cell therapy in autoimmune diseases, and as the field of CAR T cell therapy in autoimmune diseases continues to rapidly evolve, these issues will remain subject to ongoing refinement and adaptation.
Identifiants
pubmed: 39107407
doi: 10.1038/s41584-024-01139-z
pii: 10.1038/s41584-024-01139-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T-cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
pubmed: 21830940
pmcid: 3387277
doi: 10.1056/NEJMoa1103849
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR-T-cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).
pubmed: 29567707
doi: 10.1126/science.aar6711
Boyiadzis, M. M. et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J. Immunother. Cancer 6, 137 (2018).
pubmed: 30514386
pmcid: 6278156
doi: 10.1186/s40425-018-0460-5
Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. reply. N. Engl. J. Med. 388, 1284–1295 (2023).
pubmed: 37018492
doi: 10.1056/NEJMoa2210859
Mackensen, A. et al. CLDN6-specific CAR-T-cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844–2853 (2023).
pubmed: 37872225
pmcid: 10667102
doi: 10.1038/s41591-023-02612-0
Schubert, M. L. et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann. Oncol. 32, 34–48 (2021).
pubmed: 33098993
doi: 10.1016/j.annonc.2020.10.478
Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl. Cell Ther. 29, 438.e1–438.e16 (2023).
doi: 10.1016/j.jtct.2023.03.006
Rejeski, K. et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 142, 865–877 (2023).
pubmed: 37300386
doi: 10.1182/blood.2023020578
Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019).
pubmed: 30842314
pmcid: 8201923
doi: 10.1126/scitranslmed.aav1648
Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179–184 (2016).
pubmed: 27365313
pmcid: 5343513
doi: 10.1126/science.aaf6756
Mougiakakos, D. et al. CD19-targeted CAR T-cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567–569 (2021).
pubmed: 34347960
doi: 10.1056/NEJMc2107725
Mackensen, A. et al. Anti-CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022).
pubmed: 36109639
doi: 10.1038/s41591-022-02017-5
Müller, F. et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. N. Engl. J. Med. 390, 687–700. (2024).
pubmed: 38381673
doi: 10.1056/NEJMoa2308917
Taubmann, J. et al. CD19 chimeric antigen receptor T-cell treatment: unraveling the role of B-cells in systemic lupus erythematosus. Arthritis Rheumatol. 76, 497–504 (2023).
doi: 10.1002/art.42784
Wang, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. 30:ard-2024-225785; https://doi.org/10.1136/ard-2024-225785 (2024).
Taubmann, J. et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B-cell depleting antibodies. Rheumatology 63, e12–e14 (2023).
pmcid: 10765150
doi: 10.1093/rheumatology/kead330
Pecher, A. C. et al. CD19-targeting CAR T-cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329, 2154–2162 (2023).
pubmed: 37367976
pmcid: 10300719
doi: 10.1001/jama.2023.8753
Qin, C. et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T-cell therapy. Proc. Natl Acad. Sci. USA 121, e2315990121 (2024).
pubmed: 38289960
pmcid: 10861907
doi: 10.1073/pnas.2315990121
Müller, F. et al. CD19-targeted CAR T-cells in refractory anti-synthetase syndrome. Lancet 401, 815–818 (2023).
pubmed: 36930673
doi: 10.1016/S0140-6736(23)00023-5
Bergmann, C. et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR-T-cells. Ann. Rheum. Dis. 82, 1117–1120 (2023).
pubmed: 37147112
doi: 10.1136/ard-2023-223952
Merkt, W. et al. Third-generation CD19.CAR-T-cell-containing combination therapy in Scl70+ systemic sclerosis. Ann. Rheum. Dis. 83, 543–546 (2023).
doi: 10.1136/ard-2023-225174
Qin, C. et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct. Target. Ther. 8, 5 (2023).
pubmed: 36596762
pmcid: 9810610
doi: 10.1038/s41392-022-01278-3
Haghikia, A. et al. Anti-CD19 CAR T-cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104–1105 (2023).
pubmed: 37977704
doi: 10.1016/S1474-4422(23)00375-7
Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 22, 578–590 (2023).
pubmed: 37353278
pmcid: 10416207
doi: 10.1016/S1474-4422(23)00194-1
Tian, D. S. et al. B-cell lineage reconstitution underlies CAR-T-cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Mol. Med. 16, 966–987 (2024).
pubmed: 38409527
pmcid: 11018773
doi: 10.1038/s44321-024-00043-z
Fischbach, F. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5, 550–558.e2 (2024).
pubmed: 38554710
doi: 10.1016/j.medj.2024.03.002
Doglio, M. et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus. Nat. Commun. 15, 2542 (2024).
pubmed: 38538608
pmcid: 10973480
doi: 10.1038/s41467-024-46448-9
Greco, R. et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine 69, 102476 (2024).
pubmed: 38361991
pmcid: 10867419
doi: 10.1016/j.eclinm.2024.102476
Muraro, P. A. Resetting tolerance in autoimmune disease. Science 380, 470–471 (2023).
pubmed: 37141350
doi: 10.1126/science.adg7489
Del Bufalo, F. et al. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T-cells for the treatment of pediatric relapsed/refractory BCP-ALL. Blood 142, 146–157 (2023).
pubmed: 37172203
Jhita, N. & Raikar, S. S. Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies. Explor. Immunol. 2, 334–350 (2022).
pubmed: 35783107
pmcid: 9249101
doi: 10.37349/ei.2022.00054
Yang, L. et al. Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics 14, 2682 (2022).
pubmed: 36559175
pmcid: 9787894
doi: 10.3390/pharmaceutics14122682
Dimitri, A., Herbst, F. & Fraietta, J. A. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol. Cancer 21, 78 (2022).
pubmed: 35303871
pmcid: 8932053
doi: 10.1186/s12943-022-01559-z
Xin, T. et al. In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front. Oncol. 12, 809754 (2022).
pubmed: 35223491
pmcid: 8866962
doi: 10.3389/fonc.2022.809754
Mog, B. et al. Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells. Arthritis Rheumatol. 74 (2022).
Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426–1438.e11 (2018).
pubmed: 29706540
pmcid: 5984158
doi: 10.1016/j.cell.2018.03.038
Davenport, A. J. et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol. Res. 3, 483–494 (2015).
pubmed: 25711536
doi: 10.1158/2326-6066.CIR-15-0048
Gupta, S. et al. CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity. Neurol. Neuroimmunol. Neuroinflamm 10, e200080 (2023).
pubmed: 36657993
pmcid: 9853314
doi: 10.1212/NXI.0000000000200080
Mitsdoerffer, M. et al. Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity. Brain 144, 1697–1710 (2021).
pubmed: 33693558
doi: 10.1093/brain/awab093
Siddiqi, T. et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 5, 4059–4063 (2021).
pubmed: 34492703
pmcid: 8945630
doi: 10.1182/bloodadvances.2020004106
Danaher, P. et al. Single cell spatial transcriptomic profiling of childhood-onset lupus nephritis reveals complex interactions between kidney stroma and infiltrating immune cells. bioRxiv https://doi.org/10.1101/2023.11.09.566503 (2023).
Zamvil, S. S. & Hauser, S. L. Antigen presentation by B-cells in multiple sclerosis. N. Engl. J. Med. 38, 378–381 (2021).
doi: 10.1056/NEJMcibr2032177
Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4
pubmed: 35110735
pmcid: 9166916
doi: 10.1038/s41586-021-04390-6
Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034–2044 (2023).
pubmed: 37748491
doi: 10.1016/S0140-6736(23)01126-1
Voskens, C. et al. Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. Gut 72, 49–53 (2023).
pubmed: 35428657
doi: 10.1136/gutjnl-2022-327075
Furukawa, S. et al. Darvadstrocel for complex perianal fistulas in Japanese adults with Crohn’s disease: a phase 3 study. J. Crohns Colitis 17, 369–378 (2023).
pubmed: 36149832
doi: 10.1093/ecco-jcc/jjac144
Arends, S. et al. Why do drug treatments fail in Sjögren’s disease? Considerations for treatment, trial design and interpretation of clinical efficacy. Expert. Rev. Clin. Immunol. 19, 1187–1194 (2023).
pubmed: 37551702
doi: 10.1080/1744666X.2023.2234641
Nocturne, G., Pontarini, E., Bombardieri, M. & Mariette, X. Lymphomas complicating primary Sjögren’s syndrome: from autoimmunity to lymphoma. Rheumatology 60, 3513–3521 (2021).
pubmed: 30838413
doi: 10.1093/rheumatology/kez052
Sheng, L. et al. Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T-cell therapy for diffuse large B-cell lymphoma: a case report. Front. Immunol. 14, 1298815 (2023).
pubmed: 38173731
pmcid: 10762793
doi: 10.3389/fimmu.2023.1298815
Rejeski, K., Subklewe, M. & Locke, F. L. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematol. Am. Soc. Hematol. Educ. Program 2023, 198–208 (2023).
doi: 10.1182/hematology.2023000472
Doria, A. et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am. J. Med. 119, 700–706 (2006).
pubmed: 16887417
doi: 10.1016/j.amjmed.2005.11.034
Masani, N. N., Imbriano, L. J., D’Agati, V. D. & Markowitz, G. S. SLE and rapidly progressive glomerulonephritis. Am. J. Kidney Dis. 45, 950–955 (2005).
pubmed: 15861363
doi: 10.1053/j.ajkd.2004.08.047
Kammoun, K. et al. Poor prognostic factors of lupus nephritis. Saudi J. Kidney Dis. Transpl. 22, 727–732 (2011).
pubmed: 21743218
Pokeerbux, M. R. et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res. Ther. 21, 86 (2019).
pubmed: 30944015
pmcid: 6446383
doi: 10.1186/s13075-019-1867-1
Meijs, J. et al. A prediction model for progressive disease in systemic sclerosis. RMD Open 1, e000113 (2015).
pubmed: 26688749
pmcid: 4680735
doi: 10.1136/rmdopen-2015-000113
Gono, T. et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49, 1713–1719 (2010).
pubmed: 20498012
doi: 10.1093/rheumatology/keq149
Nombel, A., Fabien, N. & Coutant, F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front. Immunol. 12, 773352 (2021).
pubmed: 34745149
pmcid: 8564476
doi: 10.3389/fimmu.2021.773352
Reimann, H. et al. Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy. Blood Adv. 7, 2066–2069 (2023).
pubmed: 36206194
doi: 10.1182/bloodadvances.2022007806
Arumugakani, G. et al. Early emergence of CD19-negative human antibody-secreting cells at the plasmablast to plasma cell transition. J. Immunol. 198, 4618–4628 (2017).
pubmed: 28490574
pmcid: 5458329
doi: 10.4049/jimmunol.1501761
Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126–142 (2020).
pubmed: 32961131
pmcid: 7640763
doi: 10.1016/j.cell.2020.08.022
Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85–96 (2022).
pubmed: 34002066
doi: 10.1038/s41577-021-00547-6
Forsthuber, T. G., Cimbora, D. M., Ratchford, J. N., Katz, E. & Stüve, O. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther. Adv. Neurol. Disord. 11, 1756286418761697 (2018).
pubmed: 29593838
pmcid: 5865455
doi: 10.1177/1756286418761697
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
pubmed: 33626253
doi: 10.1056/NEJMoa2024850
Jenks, S. A. et al. Distinct effector B-cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49, 725–739 (2018).
pubmed: 30314758
pmcid: 6217820
doi: 10.1016/j.immuni.2018.08.015
Feng, J., Hu, Y., Chang, A. H. & Huang, H. CD19/BCMA CAR-T-cell therapy for refractory systemic lupus erythematosus — safety and preliminary efficacy data from a phase I clinical study. Blood 142, 4835 (2023).
doi: 10.1182/blood-2023-186669
Zeng, F. et al. Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases. J. Cell Physiol. 237, 2796–2807 (2022).
pubmed: 35486480
doi: 10.1002/jcp.30760
Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149–1155 (2020).
pubmed: 32937047
doi: 10.1056/NEJMoa2023325
Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018).
pubmed: 30135176
doi: 10.1158/2159-8290.CD-18-0442
Neelapu, S. S. CAR-T efficacy: is conditioning the key? Blood 133, 1799–1800 (2019).
pubmed: 31023743
doi: 10.1182/blood-2019-03-900928
Lickefett, B. et al. Lymphodepletion — an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front. Immunol. 14, 1303935 (2023).
pubmed: 38187393
pmcid: 10770848
doi: 10.3389/fimmu.2023.1303935
Dekker, L. et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 6, 1969–1976 (2022).
pubmed: 35134115
pmcid: 9006280
doi: 10.1182/bloodadvances.2021006700
Amini, L. et al. Preparing for CAR T-cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342–355 (2022).
pubmed: 35318469
doi: 10.1038/s41571-022-00607-3
Ghilardi, G. et al. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Adv. 8, 653–666 (2024).
pubmed: 38113468
doi: 10.1182/bloodadvances.2023011492
Nelson, M. H., Diven, M. A., Huff, L. W. & Paulos, C. M. Harnessing the microbiome to enhance cancer immunotherapy. J. Immunol. Res. 2015, 368736 (2015).
pubmed: 26101781
pmcid: 4458560
doi: 10.1155/2015/368736
Adams, E. M. et al. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J. Rheumatol. 26, 352–360 (1999).
pubmed: 9972969
Illei, G. G. et al. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology 46, 952–956 (2007).
pubmed: 17317716
doi: 10.1093/rheumatology/kem001
Koshy, M., Berger, D. & Crow, M. K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 98, 826–837 (1996).
pubmed: 8698875
pmcid: 507493
doi: 10.1172/JCI118855
Wang, S. et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c
pubmed: 29717110
pmcid: 5931508
doi: 10.1038/s41467-018-03750-7
FDA. Food and Drug Administration. FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. www.fda.gov https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed (2024).
Wang, Y. et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Adv. 5, 5290–5299 (2021).
pubmed: 34587230
pmcid: 9153033
doi: 10.1182/bloodadvances.2021004603
Walti, C. S. et al. Antibodies against vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. JCI Insight 6, e146743 (2021).
pubmed: 33914708
pmcid: 8262349
Krikau, T. et al. CAR-T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. CAR-T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403, 1627–1630 (2024).
doi: 10.1016/S0140-6736(24)00424-0
De Benedetti, F., Diomedi Camassei, F. & Locatelli, F. CAR T-cell therapy in autoimmune disease. N. Engl. J. Med. 390, 1629 (2024).
pubmed: 38692298
Ligon, J. A. et al. Fertility and CAR T-cells: current practice and future directions. Transpl. Cell Ther. 28, 605.e1–605.e8 (2022).
doi: 10.1016/j.jtct.2022.06.002
Tamirou, F. et al. Brief report: the Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Müllerian hormone. Arthritis Rheumatol. 69, 1267–1271 (2017).
pubmed: 28235250
doi: 10.1002/art.40079
Hayden, P. J. et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann. Oncol. 33, 259–275 (2022).
pubmed: 34923107
doi: 10.1016/j.annonc.2021.12.003
Peleg, A. Y. et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin. Infect. Dis. 44, 204–212 (2007).
pubmed: 17173218
doi: 10.1086/510388
Oluwole, O. O. et al. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transpl. 59, 366–372 (2024).
doi: 10.1038/s41409-023-02169-z
Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15–29 (2024).
pubmed: 37827694
doi: 10.1136/ard-2023-224762
Khan, A. N. et al. Immunogenicity of CAR-T-cell therapeutics: evidence, mechanism and mitigation. Front. Immunol. 13, 886546 (2022).
pubmed: 35677038
pmcid: 9169153
doi: 10.3389/fimmu.2022.886546
Myers, R. M. et al. Reinfusion of CD19 CAR T-cells for relapse prevention and treatment in children with acute lymphoblastic leukemia. Blood Adv. 8, 2182–2192 (2024).
pubmed: 38386999
pmcid: 11061218
doi: 10.1182/bloodadvances.2024012885
Hepburn, A. L., Narat, S. & Mason, J. C. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 49, 2243–2254 (2010).
pubmed: 20823093
doi: 10.1093/rheumatology/keq269
Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803–810 (2023).
pubmed: 37024595
pmcid: 10166099
doi: 10.1038/s41591-023-02276-w
Cook, M. R. et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 7, 32–39 (2023).
pubmed: 36260735
doi: 10.1182/bloodadvances.2022008525
Sharma, N., Reagan, P. M. & Liesveld, J. L. Cytopenia after CAR-T-cell therapy — a brief review of a complex problem. Cancers 14, 1501 (2022).
pubmed: 35326654
pmcid: 8946106
doi: 10.3390/cancers14061501
Nitta, E. et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann. Oncol. 18, 364–369 (2007).
pubmed: 17079695
doi: 10.1093/annonc/mdl393
Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584–586 (2024).
pubmed: 38265704
doi: 10.1056/NEJMp2400209
Liu A. FDA investigates ‘serious risk’ of secondary cancer following CAR T-cell treatment. Fierce Pharma. Published November 28, https://www.fiercepharma.com/pharma/fda-investigates-serious-risk-secondary-cancer-following-car-t-therapy-treatment (2023).
Chihara, D., Dores, G. M., Flowers, C. R. & Morton, L. M. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138, 785–789 (2021).
pubmed: 33822002
pmcid: 8414260
doi: 10.1182/blood.2020010497
Zhang, N. & Dalal, M. R. Incidence and prevalence of T-cell lymphoma in the EMA member states: methodology for estimation in rare malignancies of CTCL and PTCL. Value Health 22, S853 (2019).
doi: 10.1016/j.jval.2019.09.2396
Ghilardi, G. et al. T-cell lymphoma and secondary primary malignancy risk after commercial CAR T-cell therapy. Nat. Med. 30, 984–989 (2024).
pubmed: 38266761
doi: 10.1038/s41591-024-02826-w
Storgard, R., Rejeski, K., Perales, M. A., Goldman, A. & Shouval, R. T-cell malignant neoplasms after chimeric antigen receptor T-cell therapy. JAMA Oncol. 10, 826–828 (2024).
pubmed: 38635228
doi: 10.1001/jamaoncol.2024.0662
Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338–341 (2024).
pubmed: 38195751
doi: 10.1038/s41591-023-02767-w